Griffin Stephen D.'s Form 4 filing
Anika Therapeutics, Inc. (ANIK) · filed Apr 30, 2026
- Accession no.
- 0001193125-26-197887
- Filed
- Apr 30, 2026
- Trade date
- Apr 30, 2026
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $149.9K. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Griffin Stephen D.CIK 0001831125 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | Common Stock | PPurchaseAcquired | +12,200 | $12.29F1 | +$149,938 | 36,163 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $12.235 to $12.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.